FGF21 and obesity due to melanocortin 4 receptor deficiency: In the last decade, FGF21 has emerged as an appealing therapeutic for obesity and the metabolic syndrome (16–21) with pleiotropic effects on thermogenesis (22, 23), fatty acid oxidation (21), glucose metabolism (25–27), and body weight (28).